当前位置: X-MOL 学术NPG Asia Mater. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Methemoglobin as a redox-responsive nanocarrier to trigger the in situ anticancer ability of artemisinin
NPG Asia Materials ( IF 9.7 ) Pub Date : 2017-08-25 , DOI: 10.1038/am.2017.150
Huan Li , Yangjun Chen , Tingting Chen , Haijie Han , Hongxin Tong , Qiao Jin , Jian Ji

Learning from the antimalarial mechanism of artemisinin (ART) in nature, we explored methemoglobin (MHb) as a smart nanocarrier of ART, in which anticancer abilities can be turned on in situ through the upregulated reducing capacity of tumor tissue. Ultra violet–visible, electron paramagnetic resonance spectrometry and in vitro cell assessment proved that a reducing agent such as glutathione can work as an excellent biogenic trigger to reduce ferric iron in MHb to the ferrous state, activating the ability of ART to generate free radicals and resulting in cytotoxicity and apoptosis. In vivo investigations showed that the MHb–ART complex had encouraging anticancer outcomes. The bioinspired nanocarrier may pave a new way to achieve targeted toxicity to cancer cells with extremely low side effects.



中文翻译:

高铁血红蛋白作为氧化还原反应性纳米载体,可触发青蒿素的原位抗癌能力

从自然界中的青蒿素(ART)的抗疟机制中学习,我们研究了高铁血红蛋白(MHb)作为ART的智能纳米载体,其中可以通过上调肿瘤组织的还原能力原位开启抗癌能力。紫外可见电子顺磁共振光谱法和体外细胞评估证明,还原剂(如谷胱甘肽)可以作为出色的生物触发剂,将MHb中的三价铁还原为亚铁态,从而激活ART产生自由基和自由基的能力。导致细胞毒性和细胞凋亡。体内调查表明,MHb-ART复合物具有令人鼓舞的抗癌效果。受生物启发的纳米载体可能为以极低的副作用实现针对癌细胞的靶向毒性铺平道路。

更新日期:2017-08-25
down
wechat
bug